NEW YORK, Jan. 14, 2021 /PRNewswire/ -- MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow, an accomplished pharmaceutical executive, as Chief Development Officer.
MindMed's new Chief Development Officer has over a decade of experience leading drug development programs.
Researchers have started to explore the potential for psilocybin, the psychedelic drug found in "magic" mushrooms, to treat obesity.
Clinical studies continue to support the use of psilocybin for mental health. For example, a study from JAMA Psychiatry found that psilocybin “worked better than the usual antidepressant medications,” as noted by NPR.
Novamind Inc announces the expansion and optimization of its Cedar Psychiatry clinic in Utah.
MindMed commences LSD microdosing study on various health-and-wellness benefits.
Core One Labs announces a research breakthrough to help improve consistency in psilocybin dosing.
ATAI Life Sciences and MindMed Inc have the deepest psychedelics operations in this sector. Which is the better opportunity?
Cybin announces the API synthesis of multiple tryptamine derivatives.
MindCure signs LOI to make a strategic investment in ATMA, a psychedelics-assisted therapy center in Calgary, Alberta.
MindMed to Commence Groundbreaking LSD Microdosing Study Evaluating Benefits on Neuroplasticity, Sleep, Cognitive Enhancement Variables and Immune System Response on the Human Body
A county prosecutor in Michigan announced on Tuesday that his office will not be pursuing charges over possessing marijuana or entheogenic substances like psilocybin and ayahuasca — “regardless of the amount at issue.”
